| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Maternal Serum AFP
Test Code5059
CPT Codes
82105<br /> **This test is not available for California or New York patient testing. For New York patient testing use new test code 92788**
Includes
AFP, Maternal Risk Interpretation
Preferred Specimen
1 mL serum collected in a serum separator tube (SST®)
Minimum Volume
0.5 mL
Other Acceptable Specimens
Red-top tube (no gel)
Instructions
Prenatal risk assessment for open neural tube defects (NTDs).
For manual orders use “Maternal Serum Screen Requisition."
The MSAFP test in pregnant women should be performed between 15.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial MSAFP results are abnormal. Specimens submitted before 15.0 weeks or after 22.9 weeks gestation cannot be properly evaluated. Because MSAFP test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient’s (maternal) date of birth, patient’s estimated date of delivery (EDD), patient’s weight (in lbs.), patient’s race, patient diabetic status (is patient insulin-dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
For manual orders use “Maternal Serum Screen Requisition."
The MSAFP test in pregnant women should be performed between 15.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial MSAFP results are abnormal. Specimens submitted before 15.0 weeks or after 22.9 weeks gestation cannot be properly evaluated. Because MSAFP test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient’s (maternal) date of birth, patient’s estimated date of delivery (EDD), patient’s weight (in lbs.), patient’s race, patient diabetic status (is patient insulin-dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
Transport Container
Plastic screw-cap vial
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 45 days
Refrigerated: 14 days
Frozen: 45 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly lipemic
Methodology
Immunoassay (IA)
Setup Schedule
Set up: Mon-Sat; Report available: 3-5 days
Limitations
MSAFP results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. MSAFP does not screen for chromosomal abnormalities.
Reference Range
| AFP MoM: | |
| NTD | <2.50 |
| IDD | <1.90 |
| TWINS | <4.00 |
| TWINS IDD | <3.50 |
| TRIPLETS | <4.50 |
Clinical Significance
Maternal serum alpha-fetoprotein (MSAFP) is used for prenatal screening. Maternal serum Alpha-Fetoprotein (AFP) elevation is associated with open neural tube defects, multiple gestation, placental anomalies, ventral abdominal wall defects, congenital nephrosis, and oligohydramnios. Follow-up for abnormal AFP results include genetic counseling, level II or III ultrasound examination and consideration of amniocentesis for chromosome and AFP analysis. MSAFP is not to be used as a screening test for chromosomal abnormalities.
Performing Laboratory
| Quest Diagnostics Nichols Institute-San Juan Capistrano, CA |
| 33608 Ortega Highway |
| San Juan Capistrano, CA 92675-2042 |
